Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.23
+0.97 (6.36%)
At close: Mar 31, 2026, 4:00 PM EDT
15.91
-0.32 (-1.97%)
After-hours: Mar 31, 2026, 4:16 PM EDT

Theravance Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
836956466541732823
Market Cap Growth
80.66%105.25%-13.88%-26.14%-11.02%-28.05%
Enterprise Value
551.95671.9416.28483.35449.771,301
Last Close Price
16.2318.719.4111.2411.2211.05
PE Ratio
7.889.08-8.18-11.240.95-3.85
Forward PE
6.8925.83----
PS Ratio
7.788.897.239.4114.2514.87
PB Ratio
2.793.222.652.541.66-2.43
P/TBV Ratio
2.823.252.622.921.87-2.27
P/FCF Ratio
3.504.01-39.23-18.33-3.90-3.89
P/OCF Ratio
3.504.01-40.36-20.02-3.91-3.96
EV/Sales Ratio
5.146.256.478.428.7623.52
EV/EBITDA Ratio
-329.53-10.20-9.69-5.34-5.22
EV/EBIT Ratio
--186.54-8.87-8.63-4.89-5.05
EV/FCF Ratio
2.312.82-35.08-16.39-2.40-6.16
Debt / Equity Ratio
0.110.110.220.210.10-1.93
Debt / EBITDA Ratio
20.9520.94-1.22-0.99-0.62-2.69
Debt / FCF Ratio
0.180.18-4.20-1.67-0.28-3.17
Net Debt / Equity Ratio
-0.92-0.92-0.22-0.25-0.62-1.46
Net Debt / EBITDA Ratio
-133.78-133.720.941.073.27-1.99
Net Debt / FCF Ratio
-1.14-1.143.251.811.47-2.35
Asset Turnover
0.260.260.170.120.100.13
Quick Ratio
10.7310.734.894.8411.993.94
Current Ratio
10.9310.935.025.3912.314.26
Return on Equity (ROE)
38.86%44.85%-29.04%-16.86%-526.60%82.53%
Return on Assets (ROA)
-0.61%-0.70%-16.13%-12.69%-54.83%-61.06%
Return on Invested Capital (ROIC)
-1.27%-1.47%-22.88%-23.89%-128.02%-200.58%
Return on Capital Employed (ROCE)
-0.94%-0.94%-13.82%-11.97%-20.55%-77.91%
Earnings Yield
12.67%11.01%-12.22%-8.90%105.61%-25.97%
FCF Yield
28.54%24.96%-2.55%-5.45%-25.63%-25.69%
Buyback Yield / Dilution
-5.45%-5.45%11.67%24.85%-5.95%-11.41%
Total Shareholder Return
-5.45%-5.45%11.67%24.85%-5.95%-11.41%
Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q